Logo

Cira Discovery Sciences and Wistar Institute to Collaborate on Proteomics-Based Diagnostics

Feb 23, 2004

NEW YORK, Feb. 23 (GenomeWeb News) - Cira Discovery Sciences and researchers at The Wistar Institute will collaborate to develop diagnostic tests for cancer and lung disease, Cira said today.

 

Proteomics researchers at Wistar, led by David Speicher, will use Cira's computational methods to discover patterns in large proteomics data sets.

 

Cira, based in Philadelphia and founded last year, recently received a seed round of investment from BioAdvance.

 

Breaking News
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.